Court bars Amgen/Teva from sales of Sensipar. Pfizer sues Novartis. Print E-mail
By Staff   
Friday, 07 January 2011 21:07
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 7, 2011.

A U.S. district court ruling on Friday have been upheld a barring of the sale of Amgen Inc's (NASDAQ:AMGN) drug Senisipar, a kidney drug.  They also barred the sale of generic versions of the drug. Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) had sought to market a copycat version of the drug, which the court also barred.

Pfizer Inc (NYSE:PFE) has sued Novartis AG's (NYSE:NVS) Sandoz unit, accusing it of infringing its U.S. patents related to the antifungal treatment Vfend.  According to the complaint filed with the U.S. district court in Wilmington, Delaware, Pfizer said an infringement will cause irreparable injury and seeks to block Sandoz from selling any version of Vfend before the patents expire. Friday's complaint alleges that Sandoz is seeking permission from the U.S. Food and Drug Administration to sell a generic version of Vfend before the expiration of two patents issued in 1994 and 2003, respectively.Also known as voriconazole, Vfend.

Also Friday:

Athersys, Inc. (Nasdaq:ATHX) today announced that its CEO, Dr. Gil Van Bokkelen Ph.D., will present at Retail Investor

CDEX Inc. (OTCBB: CEXI) (, a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced today the signing of a new distribution agreement with HealthContrax LLC, an Iowa-based national accounts sales agency.

CONMED Corporation (NASDAQ: CNMD) announced today that it expects to report fourth quarter 2010 financial results before the market opens on Thursday, February 3, 2011, and will also hold a conference call live over the Internet at 10:00 a.m. Eastern Time that same day.

Dendreon Corporation (Nasdaq:DNDN) today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline. The Company will host a conference call at 9:00 a.m. ET to review additional details.  

EffTec International, Inc. (PINKSHEETS: EFFI), provider of a leading HVAC water-cooled chiller optimization solution, announced today that the Company has completed the installation of its innovative EffTrack™ system at six hospitals in the Baylor Health Care System.

Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today that its presentation at the 29th Annual J.P. Morgan Healthcare Conference has been rescheduled for 9:00 a.m. PT on Monday, January 10, 2011 at the Westin St. Francis Hotel in San Francisco. Questcor was originally scheduled to present at 2:00 p.m. PT on Thursday, January 13, 2011.

Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, announced today it has received approval from the New York Stock Exchange AMEX to issue RPC common stock pursuant to proposals approved by RPC's shareholders on December 3, 2010.

Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today provided an update on its business activities related to the U.S. launch and commercialization of KRYSTEXXA, a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.  

SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today it has promoted Shailesh Shah, former Vice President for Corporate Strategy, to the position of President and CEO of SOHM's US, India, and Global Operations.

Spring Creek (OTCBB: SCRK) announces that it has signed a letter of intent to license the marketing for the ReVersital® family of microdermabrasion products and all of its proprietary line extensions from M-Solo International, Inc.

WaferGen Biosystems, Inc. (OTC Bulletin Board:WGBS), a leading developer of state-of-the-art genomic analysis systems, today announced that it will present an overview of the company at the 4th Annual OneMedForum Business Development and Investment Conference for emerging healthcare and life science companies held concurrently with the JP Morgan Healthcare Conference in San Francisco, January 11-13, 2011.

Earlier in the week, Radient Pharmaceuticals (NYSE Amex: RPC) received an order valued at $10+ million for the company's FDA approved, Onko-Sure cancer test kits.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus